human coagulation factor II + human coagulation factor IX + human coagulation factor VII + human coagulation factor X + protein c + protein s: prescribing and clinical use
Focused clinical detail for use alongside current product information, local policy and patient-specific assessment.
human coagulation factor II + human coagulation factor IX + human coagulation factor VII + human coagulation factor X + protein c + protein s: clinical details
Prescribing considerations
- Restrict acquired-deficiency use to situations requiring rapid factor correction, such as major bleeding or emergency surgery.
- Seek specialist coagulation advice and balance haemostatic benefit against thrombosis or disseminated intravascular coagulation risk.
- Use a purified specific-factor product for congenital deficiency when available.
- Record the product name and batch number. Consider hepatitis A and B vaccination for repeated recipients of plasma-derived prothrombin complex products.
- Account for heparin and sodium content and the absence of paediatric use data.
Contraindications and cautions
- Hypersensitivity to an active substance or excipient.
- Known heparin allergy or previous heparin-induced thrombocytopenia.
- IgA deficiency with known anti-IgA antibodies.
Monitoring
- Clinical haemostasis and ongoing bleeding.
- INR or prothrombin time for vitamin K antagonist reversal; individual factor levels where relevant.
- Specific factor assays or global coagulation testing during major surgery.
- Signs of thrombosis or disseminated intravascular coagulation, especially in high-risk patients.
- Pulse during infusion; platelet count when heparin-induced thrombocytopenia is suspected.
- Interpret heparin-sensitive clotting tests knowing that the product contains heparin.
Clinical pharmacology
Intravenous administration makes the factors immediately available. The four vitamin K-dependent factors temporarily restore thrombin generation and fibrin formation; their circulating half-lives differ substantially.
Formulation and product differences
- Supplied as plasma-derived powder with water for injections and a transfer device.
- Vial presentations contain the same factor combination but different total quantities and reconstitution volumes.
- Contains heparin and trisodium citrate; sodium content varies by vial presentation.
human coagulation factor II + human coagulation factor IX + human coagulation factor VII + human coagulation factor X + protein c + protein s interactions
Few interactions are established, but the intended anticoagulant-reversal effect is clinically important.
Vitamin K antagonists, including warfarin
The concentrate neutralises their anticoagulant effect by replacing vitamin K-dependent clotting factors.
Sources
These sources were used to prepare and review this medicine page.
Prepared and reviewed by the iatroX editorial team.